ATAIBECKLEY INC (ATAI) competitors & alternatives
Health Care · NASDAQ
ATAIBECKLEY INC (ATAI)'s top competitors and alternatives — its most similar public companies — include COMPASS INC CLASS A (COMP), Odyssey Therapeutics, Inc. (ODTX), ELEDON PHARMACEUTICALS INC (ELDN), TYRA BIOSCIENCES INC (TYRA), DESIGN THERAPEUTICS INC (DSGN), GENERATE BIOMEDICINES INC (GENB), CLIMB BIO INC (CLYM), ANNEXON INC (ANNX), Aldeyra Therapeutics, Inc. (ALDX), ZURA BIO LTD CLASS A (ZURA), REZOLUTE INC (RZLT) and TREVI THERAPEUTICS INC (TRVI). These are ATAIBECKLEY INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ATAI competitors & alternatives
-
COMPASS INC CLASS ACOMPReal Estate
Global real estate services platform combining owned-brokerage brands (Compass, Coldwell Banker, Corcoran, Sotheby's International Realty) with a large…
$11.26 (as of 2026-07-22) · market cap $8.5B
-
Odyssey Therapeutics, Inc.ODTXHealth Care
A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates.
$18.61 (as of 2026-07-22) · market cap $865M
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
TYRA BIOSCIENCES INCTYRAHealth Care
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly…
$30.59 (as of 2026-07-22) · market cap $1.8B
-
DESIGN THERAPEUTICS INCDSGNHealth Care
A clinical-stage biotechnology company pioneering a novel class of small-molecule GeneTAC therapeutics to treat serious genetic diseases by modulating gene…
$11.78 (as of 2026-07-22) · market cap $736M
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
CLIMB BIO INCCLYMHealth Care
Clinical-stage biotech developing budoprutug, an anti-CD19 monoclonal antibody for B-cell depletion in autoimmune diseases including membranous nephropathy and…
$12.58 (as of 2026-07-22) · market cap $720M
-
ANNEXON INCANNXHealth Care
Annexon is a clinical-stage biotechnology company developing C1q-inhibitor therapies to treat neurodegenerative and autoimmune diseases driven by the classical…
$5.23 (as of 2026-07-22) · market cap $857M
-
Aldeyra Therapeutics, Inc.ALDXHealth Care
Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on…
$1.70 (as of 2026-07-22) · market cap $106M
-
ZURA BIO LTD CLASS AZURAHealth Care
Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current…
$5.40 (as of 2026-07-22) · market cap $532M
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
TREVI THERAPEUTICS INCTRVIHealth Care
Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated…
$17.36 (as of 2026-07-22) · market cap $2.5B
Not quite? Describe exactly what you want →
Peers are ATAIBECKLEY INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ATAIBECKLEY INC (ATAI).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.